3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Postoperative Complications
2
Neoplasms
2
Malnutrition
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder, Neurogenic
1
Urinary Bladder Diseases
1
Small Cell Lung Carcinoma
1
Gastrointestinal Neoplasms
1
Frailty
1
Esophagitis
1
Endometriosis
1
Cystitis, Interstitial
1
Cystitis, Hemorrhagic
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Nivolumab
2
Gemcitabine
2
Cisplatin
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
tislelizumab
1
relatlimab
1
enzalutamide
1
enfortumab vedotin
1
durvalumab
1
Water
1
Urinary Diversion
1
Standard of Care
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Multiparametric Magnetic Resonance Imaging
1
Immunonutrition Diet
1
Immune Checkpoint Inhibitors
1
Gels
1
Fluorouracil
1
Docetaxel
1
Cystoscopy
1
Cystectomy
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urinary Bladder Diseases
×
Immunonutrition Diet
×
Clear all
NCT05726786
2025-12-09
INCyst
Centre Hospitalier Universitaire Vaudois
Phase 3
Recruiting
232 enrolled